benserazide has been researched along with Restless Leg Syndrome in 20 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare efficacy and safety of the dopamine agonist pramipexole (PPX) versus reference treatment with dual release levodopa/benserazide (L/B) in de novo patients with restless legs syndrome (RLS)." | 9.15 | Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. ( Bassetti, CL; Bornatico, F; Fuhr, P; Kallweit, U; Mathis, J; Schwander, J, 2011) |
| "To investigate the long-term efficacy and safety of sustained-release (SR) in combination with regular-release (RR) levodopa/benserazide in the treatment of restless legs syndrome (RLS), an open-label, prospective, extension study of a preceding double-blind crossover trial was performed for 12 months." | 9.10 | One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? ( Collado Seidel, V; Kazenwadel, J; Kohnen, R; Oertel, W; Selzer, R; Trenkwalder, C; Wetter, TC, 2003) |
| "Twenty patients with idiopathic restless legs syndrome (RLS) were treated with 600 mg slow-release VPA and 200 mg slow-release LD+50mg benserazid in a randomized, placebo-controlled, cross-over, double-blind setting with polysomography (PSG) at the end of each 3-week treatment periods." | 6.71 | Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. ( Ehrenberg, BL; Eisensehr, I; Noachtar, S; Rogge Solti, S, 2004) |
| "Restless legs syndrome is a common neurological condition with 2-10% prevalence in the general population." | 5.32 | [Six months treatment of restless legs syndrome with levodopa/benserazide in domiciliary practice]. ( Mühlau, G, 2004) |
| "To compare efficacy and safety of the dopamine agonist pramipexole (PPX) versus reference treatment with dual release levodopa/benserazide (L/B) in de novo patients with restless legs syndrome (RLS)." | 5.15 | Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. ( Bassetti, CL; Bornatico, F; Fuhr, P; Kallweit, U; Mathis, J; Schwander, J, 2011) |
| "To investigate the long-term efficacy and safety of sustained-release (SR) in combination with regular-release (RR) levodopa/benserazide in the treatment of restless legs syndrome (RLS), an open-label, prospective, extension study of a preceding double-blind crossover trial was performed for 12 months." | 5.10 | One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? ( Collado Seidel, V; Kazenwadel, J; Kohnen, R; Oertel, W; Selzer, R; Trenkwalder, C; Wetter, TC, 2003) |
| "Thirty patients with restless legs syndrome, who initially had all responded well to treatment with levodopa and benserazide, were studied as to the long-term effect of the drugs (at least 2 years)." | 3.68 | Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. ( Kempi, V; von Scheele, C, 1990) |
| "Twenty patients with idiopathic restless legs syndrome (RLS) were treated with 600 mg slow-release VPA and 200 mg slow-release LD+50mg benserazid in a randomized, placebo-controlled, cross-over, double-blind setting with polysomography (PSG) at the end of each 3-week treatment periods." | 2.71 | Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. ( Ehrenberg, BL; Eisensehr, I; Noachtar, S; Rogge Solti, S, 2004) |
| "Six patients with restless legs syndrome (RLS) and periodic movements during sleep (PMS) received placebo or L-dopa in a double-blind study." | 2.66 | Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. ( Brodeur, C; Godbout, R; Marinier, R; Montplaisir, J, 1988) |
| "Sixteen patients with symptoms of restless legs syndrome and resulting insomnia are included in this study." | 2.66 | Restless legs syndrome treatment with dopaminergic drugs. ( Akpinar, S, 1987) |
| "Improving sleep quality in patients with obstructive sleep apnea (OSA) by positive airway pressure therapy is associated with a decrease of blood pressure (BP)." | 1.72 | The impact of treatment of periodic limb movements in sleep on blood pressure in patients with and without sleep apnea. ( Babel, N; Bertram, S; Büchner, N; Doevelaar, A; Mühlberger, D; Racovitan, D; Rohn, B; Seibert, FS; Seidel, M; Toma, D; Wang, S; Westhoff, TH, 2022) |
| "Restless legs syndrome is a common neurological condition with 2-10% prevalence in the general population." | 1.32 | [Six months treatment of restless legs syndrome with levodopa/benserazide in domiciliary practice]. ( Mühlau, G, 2004) |
| " No addiction to the drugs, and in particular no need of a dosage increase was observed during the whole period of 18 months." | 1.29 | [Restless legs syndrome. Report of experience]. ( Grandjean, P, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (25.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toma, D | 1 |
| Bertram, S | 1 |
| Racovitan, D | 1 |
| Seidel, M | 1 |
| Doevelaar, A | 1 |
| Seibert, FS | 1 |
| Rohn, B | 1 |
| Babel, N | 1 |
| Mühlberger, D | 1 |
| Büchner, N | 1 |
| Wang, S | 1 |
| Westhoff, TH | 1 |
| Tischendorf, JJ | 1 |
| Karges, W | 1 |
| Schöfl, C | 1 |
| Bassetti, CL | 1 |
| Bornatico, F | 1 |
| Fuhr, P | 1 |
| Schwander, J | 1 |
| Kallweit, U | 1 |
| Mathis, J | 1 |
| Saletu, M | 1 |
| Anderer, P | 1 |
| Högl, B | 1 |
| Saletu-Zyhlarz, G | 1 |
| Kunz, A | 1 |
| Poewe, W | 1 |
| Saletu, B | 1 |
| Trenkwalder, C | 3 |
| Collado Seidel, V | 1 |
| Kazenwadel, J | 2 |
| Wetter, TC | 1 |
| Oertel, W | 1 |
| Selzer, R | 1 |
| Kohnen, R | 3 |
| Eisensehr, I | 1 |
| Ehrenberg, BL | 1 |
| Rogge Solti, S | 1 |
| Noachtar, S | 1 |
| Mühlau, G | 2 |
| Stiasny-Kolster, K | 1 |
| Möller, JC | 1 |
| Oertel, WH | 1 |
| Evans, AH | 1 |
| Butzkueven, H | 1 |
| Akpinar, S | 2 |
| Grandjean, P | 1 |
| Stiasny, K | 1 |
| Pollmächer, T | 1 |
| Wetter, T | 1 |
| Schwarz, J | 1 |
| Krüger, HP | 1 |
| Ramm, S | 1 |
| Künzel, M | 1 |
| de Mello, MT | 1 |
| Poyares, DL | 1 |
| Tufik, S | 1 |
| Lauerma, H | 1 |
| von Scheele, C | 2 |
| Kempi, V | 1 |
| Brodeur, C | 1 |
| Montplaisir, J | 1 |
| Godbout, R | 1 |
| Marinier, R | 1 |
| Gillman, MA | 1 |
| Sandyk, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day)[NCT00144209] | Phase 3 | 58 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 trials available for benserazide and Restless Leg Syndrome
| Article | Year |
|---|---|
Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
Topics: Adult; Aged; Benserazide; Benzothiazoles; Cross-Over Studies; Dopamine Agonists; Dose-Response Relat | 2011 |
Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Cross-Over Studies; Delayed-Action Preparations; Double | 2003 |
One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Delayed-Action Preparations; Dru | 2003 |
Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid.
Topics: Adult; Aged; Anticonvulsants; Antiparkinson Agents; Benserazide; Cross-Over Studies; Double-Blind Me | 2004 |
L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Double-Blind Method; Drug Therap | 1995 |
Treatment of periodic leg movements with a dopaminergic agonist in subjects with total spinal cord lesions.
Topics: Adult; Benserazide; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Humans; Levodopa; Ma | 1999 |
Levodopa in restless legs.
Topics: Adolescent; Adult; Aged; Benserazide; Capsules; Child; Clinical Trials as Topic; Double-Blind Method | 1986 |
Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.
Topics: Benserazide; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle A | 1988 |
Restless legs syndrome treatment with dopaminergic drugs.
Topics: Adult; Aged; Benserazide; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Female; Huma | 1987 |
11 other studies available for benserazide and Restless Leg Syndrome
| Article | Year |
|---|---|
The impact of treatment of periodic limb movements in sleep on blood pressure in patients with and without sleep apnea.
Topics: Aged; Benserazide; Blood Pressure; Dopamine Agonists; Humans; Levodopa; Middle Aged; Restless Legs S | 2022 |
Catecholamine excess in a patient with restless legs syndrome treated with levodopa and benserazide.
Topics: Adult; Antiparkinson Agents; Benserazide; Catecholamines; Diagnosis, Differential; Drug Combinations | 2009 |
[What helps in the treatment of restless legs?].
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Agents; Dose-Response R | 2004 |
[Six months treatment of restless legs syndrome with levodopa/benserazide in domiciliary practice].
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Dopamine Agents; Drug Therapy, Combination; Female; Hum | 2004 |
Validation of the "L-DOPA test" for diagnosis of restless legs syndrome.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benserazide; Cohort Studies; Diagnosis, Differ | 2006 |
Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis.
Topics: Adult; Benserazide; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Drug Ther | 2007 |
Treatment of restless legs syndrome with levodopa plus benserazide.
Topics: Adult; Benserazide; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Restless Legs Syndrome | 1982 |
[Restless legs syndrome. Report of experience].
Topics: Benserazide; Codeine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Mal | 1993 |
Nocturnal wandering caused by restless legs and short-acting benzodiazepines.
Topics: Anti-Anxiety Agents; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; My | 1991 |
Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benserazide; Bromocriptine; Child; Dopamine Agents; Drug | 1990 |
Opioids, dopamine, and restless legs syndrome.
Topics: Benserazide; Dopamine; Humans; Levodopa; Narcotics; Restless Legs Syndrome | 1985 |